Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Prevalence of non-treatment following pancreatic cancer diagnosis in the United States: A population-based analysis, 2016–2022.

Canan Dilay Dirican, Raj Nandan Chennuri, Aqsa Zoey Sorathia et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16357

e16357 Background: Pancreatic cancer is an aggressive malignancy for which cancer-directed therapy can improve outcomes wh...

Spatial localization of epithelial-mesenchymal transition and immune niches in non-small cell lung cancer via interpretable gene set activity analysis.

Andrew J. Yang, Chichun Tan, Ying Ma Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20556

e20556 Background: The tumor microenvironment (TME) in non-small cell lung cancer (NSCLC) is highly heterogeneous, with sp...

Indocyanine green fluorescence–guided navigation during gastrectomy for resectable gastric cancer: A systematic review and meta-analysis.

Sergio Morales Acosta, Lluvia Murillo, Jorge Sandoval et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16147

e16147 Background: Radical gastrectomy with lymphadenectomy is the standard surgical approach for curative treatmentof gas...

Enhanced predictive value of KELIM for surgical resectability in HRD-positive high-grade serous ovarian cancer.

Mayerly Castrillón Sánchez, Gabriel Levin, Lawrie Shahbazian et al. Jun 01, 2026 pp. 5590-5590 10.1200/jco.2026.44.16_suppl.5590

5590 Background: Neoadjuvant chemotherapy followed by interval debulking surgery is commonly used in the management of adv...

EfficientNetV2-guided knowledge distillation for breast ultrasound diagnosis: Scalable deep learning with international clinical validation.

Sophia Ahmed, Elangovan Krishnan, Jansi Rani Sethuraj et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12571

e12571 Background: Breast cancer remains a leading cause of cancer-related morbidity worldwide, with imaging central to ea...

Major adverse cardiovascular events among prostate cancer patients in the VA, stratified by HIV status and androgen deprivation therapy.

Debanjan Pain, Yongquan Dong, Christine Hartman et al. Jun 01, 2026 pp. 12157-12157 10.1200/jco.2026.44.16_suppl.12157

12157 Background: Despite the rapidly increasing trend in incidence of prostate cancer among persons with HIV (PWH), compr...

Total neoadjuvant immunotherapy plus chemotherapy in Borrmann type IV gastric cancer (PERISCOPE-01 study): An open-label, single-arm, phase 2 trial.

Haibo Qiu, Chao Ding, Dandan Li et al. Jun 01, 2026 pp. 4079-4079 10.1200/jco.2026.44.16_suppl.4079

4079 Background: Borrmann type IV (Borrmann-IV) gastric cancer (GC), or linitis plastica, is marked by diffuse infiltratio...

Real-world efficacy and safety of tarlatamab in small cell lung cancer and extrapulmonary neuroendocrine carcinoma.

Jun Chih Wang, Vera Bulakhova, Daniel Rosas et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20166

e20166 Background: Patients with extensive-stage small cell lung cancer (ES-SCLC) and extrapulmonary neuroendocrine carcin...

Patterns of failure and efficacy for unresectable or recurrent gastric and gastroesophageal junction adenocarcinoma after immune checkpoint inhibitor therapy: A retrospective study.

Fengxue Li, Lili Qiao, Xinquan Liang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16491

e16491 Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have been incorporated into clinical gui...

Clinical outcomes of local treatments for oligoprogressive or oligorecurrent small cell lung cancer.

Adrien Mathieu, Guillaume Pamart, Marion Klotz et al. Jun 01, 2026 pp. 8090-8090 10.1200/jco.2026.44.16_suppl.8090

8090 Background: The role of local treatments in patients with oligoprogressive or oligorecurrent small cell lung cancer (...

Intersecting risks: Myelodysplastic neoplasms and cardiovascular disease mortality in older adults across the United States, 1999–2020.

Mudasar Nisar, Fiqe Khan, Sohaib Aftab Ahmad Chaudhry et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18581

e18581 Background: Myelodysplastic syndrome (MDS) predominantly affects older adults and carry substantial mortality. Card...

Limitations in US cancer screening rate data and opportunities for improvement.

Gary George Gustavsen, Owen Fahey, Elissa Quinn et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22535

e22535 Background: Cancer screening is a cornerstone of cancer control, yet screening participation remains inconsistent a...

Predicting infiltrative hepatocellular carcinoma and efficacy of combination treatment for conversion therapy based on pretreatment CT/MR features.

Yingwen Hou, Zhimei Huang, Jin-Hua Huang Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16290

e16290 Background: Infiltrative HCC (iHCC) has been demonstrated to exhibit the highest malignant potential and poorest pr...

ASPRIA: A single-arm phase 2 trial of atezolizumab with sacituzumab govitecan to prevent recurrence in triple-negative breast cancer.

Payal Deepak Shah, Angela DeMichele, Paul Wileyto et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps644

TPS644 Background: Despite marked improvements in neoadjuvant chemoimmunotherapy (NACT) and adjuvant treatment for patient...

Palliative neck radiation therapy (RT) in combination with lenvatinib/pembrolizumab (L/P) in BRAF wild-type anaplastic thyroid cancer (BRAF-WT ATC).

Anna Lawless, Isabelle Fournier, Maria E. Cabanillas et al. Jun 01, 2026 pp. 6117-6117 10.1200/jco.2026.44.16_suppl.6117

6117 Background: BRAF-WT ATC carries a poor prognosis due to limited effective therapies and rapid, often fatal locoregion...

Conditional survival in advanced-stage epithelial ovarian cancer: Implications for survivorship planning and patient counseling.

Aydan Farzaliyeva, Hüseyin Akıllı, Ozden Altundag et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17500

e17500 Background: Advanced-stage epithelial ovarian cancer (EOC) is characterized by biological heterogeneity and...

Cytokine profiles in HPV-associated cervical intraepithelial neoplasia.

Aleksandra Nikolaevna Riger, Nataliy Kharchenko, Irina Antonova et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22517

e22517 Background: Persistent high-risk human papillomavirus (HPV) infection is a well-established driver of cervical intr...

Safety and efficacy results from a first-in-human, phase 1/2 study of ASKG915, an anti-PD-1/pro-IL-15 bifunctional fusion protein, for patients with advanced solid tumors.

Jiajia Li, Jian Zhang, Lin Wu et al. Jun 01, 2026 pp. 2607-2607 10.1200/jco.2026.44.16_suppl.2607

2607 Background: ASKG915 is a bifunctional fusion protein of PD-1 antibody fused with an IL-15 prodrug. Preclinical studie...

A phase 3 trial of adagloxad simolenin/OBI-821 in patients with high-risk early-stage triple-negative breast cancer.

Hope S. Rugo, Bernardo Leon Rapoport, Javier Cortés et al. Jun 01, 2026 pp. 2551-2551 10.1200/jco.2026.44.16_suppl.2551

2551 Background: Adagloxad simolenin (AS) is a therapeutic cancer vaccine composed of Globo H linked to the carrier protei...

Impact of remote therapeutic monitoring on time to discontinuation and acute care events among patients treated with immune checkpoint inhibitors.

Benjamin Avi Derman, Michael A. Kolodziej, James H. Essell et al. Jun 01, 2026 pp. 11108-11108 10.1200/jco.2026.44.16_suppl.11108

11108 Background: Immune checkpoint inhibitors (ICI) are used to treat several solid tumors but can cause serious toxiciti...

Factors associated with mood and anxiety disorders in cancer survivors: A systematic review and meta-analysis.

Mingyi Li, Xuanyu Zhou, Zhengyi Deng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24106

e24106 Background: Mood and anxiety disorders affect up to 38% of cancer survivors and are associated with poorer quality...

Safety and preliminary efficacy of a novel armored mesothelin-targeted CAR-T therapy in advanced solid tumors.

Changsong Qi, Wei Li, Panpan Zhang et al. Jun 01, 2026 pp. 2543-2543 10.1200/jco.2026.44.16_suppl.2543

2543 Background: UCMYM802 is an autologous mRNA-electroporated CAR-T cell therapy targeting mesothelin (MSLN), incorporati...

Lipid-lowering therapy use among cancer survivors undergoing lung cancer screening: A cross-sectional analysis.

Sri Gopalsamy Ramaswamy, Eyerusalem Zewde, Akila Anandarajah et al. Jun 01, 2026 pp. 12029-12029 10.1200/jco.2026.44.16_suppl.12029

12029 Background: Cardiovascular disease (CVD) causes 56% of non-cancer deaths among cancer survivors, yet lipid-lowering...

First-line maintenance therapy patterns in <i>BRCA</i> wild-type and HRD-negative advanced epithelial ovarian cancer: A European real-world study.

Christine Kieu Loan Maï, Stergios Boussios, Mario Uccello et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17552

e17552 Background: Maintenance therapy is central to the management of advanced epithelial ovarian cancer (AEOC), yet real...

Uterine serous and clear cell carcinomas: Hormonal profile and expression of steroid hormone receptors in mitochondria.

Anna Petrovna Menshenina, Elena M. Frantsiyants, Valeria Bandovkina et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17624

e17624 Background: Uterine serous carcinoma (USC) and clear cell carcinoma (CCC) are rare but aggressive histological subt...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page